JP2013523758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523758A5 JP2013523758A5 JP2013502785A JP2013502785A JP2013523758A5 JP 2013523758 A5 JP2013523758 A5 JP 2013523758A5 JP 2013502785 A JP2013502785 A JP 2013502785A JP 2013502785 A JP2013502785 A JP 2013502785A JP 2013523758 A5 JP2013523758 A5 JP 2013523758A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- aggression
- formulation
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 206010001488 Aggression Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28278710P | 2010-03-31 | 2010-03-31 | |
| US61/282,787 | 2010-03-31 | ||
| PCT/US2011/030444 WO2011123497A1 (en) | 2010-03-31 | 2011-03-30 | Stabilized formulations of cns compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015204851A Division JP6529416B2 (ja) | 2010-03-31 | 2015-10-16 | Ｃｎｓ化合物の安定化製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523758A JP2013523758A (ja) | 2013-06-17 |
| JP2013523758A5 true JP2013523758A5 (enExample) | 2014-05-22 |
| JP6063377B2 JP6063377B2 (ja) | 2017-01-18 |
Family
ID=44709952
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502785A Active JP6063377B2 (ja) | 2010-03-31 | 2011-03-30 | Ｃｎｓ化合物の安定化製剤 |
| JP2015204851A Active JP6529416B2 (ja) | 2010-03-31 | 2015-10-16 | Ｃｎｓ化合物の安定化製剤 |
| JP2017161044A Active JP6588948B2 (ja) | 2010-03-31 | 2017-08-24 | Ｃｎｓ化合物の安定化製剤 |
| JP2019125672A Active JP6759426B2 (ja) | 2010-03-31 | 2019-07-05 | Ｃｎｓ化合物の安定化製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015204851A Active JP6529416B2 (ja) | 2010-03-31 | 2015-10-16 | Ｃｎｓ化合物の安定化製剤 |
| JP2017161044A Active JP6588948B2 (ja) | 2010-03-31 | 2017-08-24 | Ｃｎｓ化合物の安定化製剤 |
| JP2019125672A Active JP6759426B2 (ja) | 2010-03-31 | 2019-07-05 | Ｃｎｓ化合物の安定化製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8748472B2 (enExample) |
| EP (3) | EP3572074B1 (enExample) |
| JP (4) | JP6063377B2 (enExample) |
| AU (1) | AU2011235222B2 (enExample) |
| CA (1) | CA2793222C (enExample) |
| ES (3) | ES2643497T3 (enExample) |
| MX (1) | MX2012010829A (enExample) |
| WO (1) | WO2011123497A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362853B (es) | 2008-12-19 | 2019-02-20 | Supernus Pharmaceuticals Inc | Uso de molindona para el tratamiento de agresión. |
| EP3572074B1 (en) * | 2010-03-31 | 2021-01-06 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of molindone |
| AU2013344920A1 (en) * | 2012-11-13 | 2015-04-30 | Supernus Pharmaceuticals, Inc. | Method of treatment of aggression |
| WO2017189892A1 (en) | 2016-04-29 | 2017-11-02 | Supernus Pharmaceuticals, Inc. | Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression |
| US20180078516A1 (en) * | 2016-09-19 | 2018-03-22 | Innovazone Labs LLC | Pharmaceutical Composition of Ibuprofen Sodium for Oral Administration |
| WO2019014201A1 (en) * | 2017-07-10 | 2019-01-17 | Apicore Us Llc | MOLINDONE COMPOSITIONS WITH EXTENDED RELEASE |
| EP4212149A1 (en) | 2022-01-18 | 2023-07-19 | Rijksuniversiteit Groningen | Oral dosage forms of acid-labile salt and methods and uses related thereto |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148896A (en) * | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US6489319B2 (en) | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| CA2352211C (en) * | 1999-09-30 | 2009-03-24 | Edward Mendell Co., Inc. | Sustained release matrix systems for highly soluble drugs |
| FR2814463B1 (fr) | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
| US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
| US6613763B2 (en) * | 2001-04-20 | 2003-09-02 | Mgi Applied Genomics | Use of molindone to treat oppositional defiant disorder and conduct disorder |
| CA2452738C (en) * | 2001-07-04 | 2011-06-14 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
| DE10149108A1 (de) | 2001-10-05 | 2003-04-30 | Degussa Bioactives Deutschland | Verwendung von Phosphatidylserin zur Behandlung des Aufmerksamkeits-Defizit-Syndroms (ADHS) |
| AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| US20060147527A1 (en) | 2002-12-13 | 2006-07-06 | Cilag Ag | Controlled release preparations comprising tramadol and topiramate |
| US20050004105A1 (en) | 2003-01-29 | 2005-01-06 | Emer Leahy | Treatment for a attention-deficit hyperactivity disorder |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| US7761144B2 (en) | 2004-03-18 | 2010-07-20 | University Of Virginia Patent Foundation | Method, apparatus, and computer program product for stochastic psycho-physiological assessment of attentional impairments |
| MXPA06013762A (es) | 2004-05-27 | 2007-02-08 | Warner Lambert Co | Combinacion de atomoxetina y un agonista del receptor 5t1a para el tratamiento de trastorno de hiperactividad con deficit de atencion y otros trastornos. |
| US20070197525A1 (en) | 2004-06-14 | 2007-08-23 | Cid-Nunez Jose M | Novel tetracyclic tetrahydrofuran derivatives |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| BRPI0716196A2 (pt) | 2006-08-31 | 2013-11-12 | Eurand Inc | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. |
| JP2008189616A (ja) | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | 注意欠陥多動性障害の治療薬 |
| GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8637080B2 (en) * | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
| MX362853B (es) | 2008-12-19 | 2019-02-20 | Supernus Pharmaceuticals Inc | Uso de molindona para el tratamiento de agresión. |
| EP3572074B1 (en) | 2010-03-31 | 2021-01-06 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of molindone |
| SE536078C2 (sv) | 2010-10-09 | 2013-04-30 | Core Link Ab | Anordning för bearbetning av hylsor |
-
2011
- 2011-03-30 EP EP19184602.1A patent/EP3572074B1/en active Active
- 2011-03-30 ES ES11763349.5T patent/ES2643497T3/es active Active
- 2011-03-30 CA CA2793222A patent/CA2793222C/en active Active
- 2011-03-30 EP EP11763349.5A patent/EP2552423B1/en active Active
- 2011-03-30 MX MX2012010829A patent/MX2012010829A/es active IP Right Grant
- 2011-03-30 US US13/075,607 patent/US8748472B2/en active Active
- 2011-03-30 ES ES19184602T patent/ES2852899T3/es active Active
- 2011-03-30 ES ES17180576T patent/ES2756711T3/es active Active
- 2011-03-30 AU AU2011235222A patent/AU2011235222B2/en active Active
- 2011-03-30 JP JP2013502785A patent/JP6063377B2/ja active Active
- 2011-03-30 WO PCT/US2011/030444 patent/WO2011123497A1/en not_active Ceased
- 2011-03-30 EP EP17180576.5A patent/EP3269363B1/en active Active
-
2014
- 2014-04-25 US US14/261,709 patent/US10149853B2/en active Active
-
2015
- 2015-10-16 JP JP2015204851A patent/JP6529416B2/ja active Active
-
2017
- 2017-08-24 JP JP2017161044A patent/JP6588948B2/ja active Active
-
2018
- 2018-10-30 US US16/175,207 patent/US11077114B2/en active Active
-
2019
- 2019-07-05 JP JP2019125672A patent/JP6759426B2/ja active Active
-
2021
- 2021-06-25 US US17/358,920 patent/US20210322429A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2726511T (lt) | Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui | |
| JP2016515522A5 (enExample) | ||
| JP2012179069A5 (enExample) | ||
| IL227990B (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases | |
| MX380147B (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida. | |
| JP2013514381A5 (enExample) | ||
| JP2013523758A5 (enExample) | ||
| DOP2015000012A (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
| JP2014221779A5 (enExample) | ||
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| EP2736341A4 (en) | COMPOSITIONS AND METHODS FOR COMBATING EARLY FUSARIOSIS | |
| WO2013057570A3 (en) | Acrylic polymer formulations | |
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| JP2014530840A5 (enExample) | ||
| WO2013003669A3 (en) | Compositions, methods of use, and methods of treatment | |
| LT4104824T (lt) | Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą | |
| WO2013007596A3 (en) | Oral treatment of inflammatory bowel disease | |
| PL2718434T3 (pl) | Kompozycje i sposoby leczenia choroby trzewnej | |
| BR112014009789A2 (pt) | cisteamina no tratamento da doença fibrótica | |
| WO2016011049A3 (en) | Compositions and methods for disease treatment using nanoparticle delivered compounds | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| WO2015080980A3 (en) | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators | |
| WO2015031198A3 (en) | Bendamustine pharmaceutical compositions | |
| JP2017516883A5 (enExample) |